Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010.

scientific article

Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1033998707
P356DOI10.1186/1756-0500-6-82
P932PMC publication ID3606324
P698PubMed publication ID23497453
P5875ResearchGate publication ID236051890

P50authorNigel RawsonQ67562857
P2093author name stringJorge A Ross Terres
P2860cites workEffect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesQ22250883
Changes in glitazone use among office-based physicians in the U.S., 2003-2009.Q33751542
Database size and power to detect safety signals in pharmacovigilanceQ36984256
Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning eventsQ37240896
Temporal trends in anti-diabetes drug use in TRICARE following safety warnings in 2007 about rosiglitazoneQ37572625
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications.Q41807349
Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.Q43703608
New use of rosiglitazone decreased following publication of a meta-analysis suggesting harmQ46471450
P275copyright licenseCreative Commons Attribution 2.0 GenericQ19125117
P6216copyright statuscopyrightedQ50423863
P921main subject(RS)-rosiglitazoneQ424771
CanadaQ16
P304page(s)82
P577publication date2013-03-05
P1433published inBMC Research NotesQ15762797
P1476titleRosiglitazone use and associated adverse event rates in Canada between 2004 and 2010
P478volume6

Reverse relations

cites work (P2860)
Q43636050Fucosylated chondroitin sulfate from Acaudina molpadioides improves hyperglycemia via activation of PKB/GLUT4 signaling in skeletal muscle of insulin resistant mice
Q38644070Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies.
Q35792497Rosiglitazone use and associated adverse event rates in Canada: an updated analysis

Search more.